

BUPRENORPHINE SUBCUT DEPOT

BRAND NAME	BUVIDAL WEEKLY, BUVIDAL MONTHLY, SUBLOCADE
DRUG CLASS	Strong opioid analgesic with mixed agonist/antagonist activity
AVAILABILITY	<p>Buvidal Weekly prefilled syringe contains 8 mg/0.16 mL, 16 mg/0.32 mL, 24 mg/0.48 mL or 32 mg/0.64 mL of buprenorphine. Also contains phosphatidyl choline (soybean), glyceryl dioleate and ethanol (less than 100 mg).^{1,2}</p> <p>Buvidal Monthly prefilled syringe contains 64 mg/0.18 mL, 96 mg/0.27 mL, 128 mg/0.36 mL or 160 mg/0.45 mL of buprenorphine. Also contains phosphatidyl choline (soybean), glyceryl dioleate and N-methyl-2-pyrrolidone.¹</p> <p>Buvidal solutions are clear and yellow.¹</p> <p>Sublocade prefilled syringe contains 100 mg/0.5 mL, or 300 mg/1.5 mL of buprenorphine. Also contains polyglactin, N-methyl-2-pyrrolidone.¹</p> <p>Controlled drug: use must be recorded.</p>
WARNING	<p>Do not give intravenously. May cause serious harm.¹</p> <p>Patients must be stabilised on sublingual buprenorphine for at least 7 days before the first injection.</p> <p>May cause respiratory depression when given in high or repeated doses or to patients who are elderly or have compromised respiratory function. Monitor at-risk patients closely.¹ See SPECIAL NOTES</p> <p>Naloxone may not be effective in reversing respiratory depression caused by buprenorphine.¹</p>
pH	No information
PREPARATION	Sublocade: allow 15 minutes for the syringe to reach room temperature. ¹
STABILITY	Buvidal: store below 25 °C. Do not refrigerate or freeze. ¹ Sublocade: store at 2 to 8 °C. Do not freeze. Stable for 28 days below 25 °C. ¹
ADMINISTRATION	
IM injection	Contraindicated ¹
SUBCUT injection	<p>Buvidal: inject slowly into the thigh, buttock, abdomen or upper arm.¹</p> <p>Sublocade: inject slowly into the abdomen.¹</p> <p>Rotate the site of the injection.¹</p>
IV injection	Contraindicated ¹
IV infusion	Contraindicated ¹
COMPATIBILITY	Do not mix with other medicines
INCOMPATIBILITY	No information
SPECIAL NOTES	<p>Patients with compromised respiratory function include those with obstructive sleep apnoea and those concurrently taking medicines that can cause CNS or respiratory depression such as benzodiazepines, alcohol and other opioids.</p> <p>Injection site pain, pruritis and erythema are common.¹</p> <p>After an injection of Sublocade there will be a palpable lump at the injection site that will dissolve over time. Advise patients not to rub or massage the site.¹</p> <p>To avoid missed doses Buvidal Weekly can be given within two days and Buvidal Monthly can be given within a week of the scheduled due date. For Sublocade, occasional delays of up to two weeks are not expected to have a significant impact on clinical effect.¹</p>

REFERENCES

1. Product information. Available from www.tga.gov.au. Accessed 27/05/2022.
2. Consumer medicine information. Available from www.tga.gov.au. Accessed 28/01/2021.